ciglitazone has been researched along with Primary Peritonitis in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| " TZDs were first used as orally bioavailable insulin-sensitizing agents." | 1.32 | Thiazolidinedione inhibition of peritoneal inflammation. ( Chao, VA; Hornung, D; Taylor, RN; Vigne, JL; Wallwiener, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hornung, D | 1 |
| Chao, VA | 1 |
| Vigne, JL | 1 |
| Wallwiener, D | 1 |
| Taylor, RN | 1 |
1 other study available for ciglitazone and Primary Peritonitis
| Article | Year |
|---|---|
Thiazolidinedione inhibition of peritoneal inflammation.
Topics: Animals; Chemokine CCL5; Disease Models, Animal; Endometriosis; Female; Interleukin-1; Leukocyte Cou | 2003 |